{"id":50461,"date":"2025-12-11T22:43:25","date_gmt":"2025-12-11T14:43:25","guid":{"rendered":"https:\/\/flcube.com\/?p=50461"},"modified":"2025-12-11T22:43:28","modified_gmt":"2025-12-11T14:43:28","slug":"bleecker-bio-formation-licenses-lynks-cns-penetrant-tyk2-inhibitor-lnk01006-in-605-m-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50461","title":{"rendered":"Bleecker Bio (Formation) Licenses Lynk\u2019s CNS\u2011Penetrant TYK2 Inhibitor LNK01006 in $605\u202fM Deal"},"content":{"rendered":"\n<p><strong>Lynk Pharmaceuticals Co., Ltd.<\/strong> and <strong>Formation Bio<\/strong> announced that <strong>Bleecker Bio<\/strong>, a newly formed Formation subsidiary, has secured <strong>exclusive global rights (ex\u2011Greater China)<\/strong> to <strong>LNK01006<\/strong>, Lynk\u2019s next\u2011generation, CNS\u2011penetrant, allosteric <strong>TYK2 inhibitor<\/strong>. Lynk will receive an <strong>upfront payment (undisclosed)<\/strong>, up to <strong>USD\u202f605\u202fmillion<\/strong> in milestones, <strong>tiered royalties<\/strong>, and an <strong>equity stake<\/strong> in Bleecker Bio. <strong>Pacific Bridge NY<\/strong> will co\u2011invest as a minority partner.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-structure\">Transaction Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Asset Licensed<\/strong><\/td><td>LNK01006 (oral, CNS\u2011penetrant TYK2 inhibitor)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Global (excluding Greater China)<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>Undisclosed cash payment<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to USD\u202f605\u202fmillion (development, regulatory, commercial)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered, graded percentages on net sales<\/td><\/tr><tr><td><strong>Equity<\/strong><\/td><td>Lynk holds minority stake in Bleecker Bio<\/td><\/tr><tr><td><strong>Co\u2011Investor<\/strong><\/td><td>Pacific Bridge NY (minority investor in Bleecker Bio)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-differentiation\">Drug Profile &amp; Differentiation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>LNK01006<\/th><th>Competitive Landscape<\/th><\/tr><\/thead><tbody><tr><td><strong>Mechanism<\/strong><\/td><td>Allosteric TYK2 inhibitor; highly selective for TYK2\u2011mediated cytokine signaling<\/td><td>BMS\u2019s Sotyktu (deucravacitinib) is first\u2011in\u2011class, approved in psoriasis<\/td><\/tr><tr><td><strong>CNS Penetration<\/strong><\/td><td>Optimized for <strong>central immunomodulation<\/strong>; crosses blood\u2011brain barrier<\/td><td>Limited CNS\u2011active TYK2 inhibitors in clinic; addresses neuroinflammation<\/td><\/tr><tr><td><strong>Selectivity<\/strong><\/td><td>Best\u2011in\u2011class potential; minimal off\u2011target JAK family inhibition<\/td><td>Improves safety profile vs. broader JAK inhibitors<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Autoimmune\/inflammatory disorders with CNS involvement (e.g., MS, NMOSD, lupus cerebritis)<\/td><td>Expands TYK2 class beyond skin\/joint diseases<\/td><\/tr><tr><td><strong>Stage<\/strong><\/td><td>Ready for IND\u2011enabling studies; Phase\u202f1 planned H2\u202f2026<\/td><td>Early\u2011to\u2011mid stage competitive position<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TYK2 Inhibitor Market:<\/strong> Projected <strong>$8\u201112\u202fbillion<\/strong> by 2030 if successful in multiple indications; current growth driven by psoriasis, psoriatic arthritis, and expanding into lupus, IBD.<\/li>\n\n\n\n<li><strong>CNS Autoimmune Market:<\/strong> <strong>Multiple sclerosis<\/strong> ($23\u202fB market), <strong>NMOSD<\/strong> ($2\u202fB), and <strong>lupus cerebritis<\/strong> (unmet need) represent <strong>$30\u202fbillion+<\/strong> addressable market lacking oral, CNS\u2011penetrant immunomodulators.<\/li>\n\n\n\n<li><strong>LNK01006 Peak Sales Forecast:<\/strong> <strong>$1.5\u20112.0\u202fbillion<\/strong> globally (ex\u2011China) by 2033 if approved in 2\u20113 neuroinflammatory indications.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Lynk:<\/strong> Validates <strong>proprietary TYK2 platform<\/strong>; retains <strong>Greater China rights<\/strong> for potential <strong>\u00a53\u20115\u202fbillion<\/strong> domestic market; secures <strong>non\u2011dilutive capital<\/strong> and equity upside via Bleecker Bio stake.<\/li>\n\n\n\n<li><strong>For Formation\/Bleecker Bio:<\/strong> Establishes dedicated <strong>CNS\u2011immunology subsidiary<\/strong> with a <strong>differentiated TYK2 asset<\/strong>; leverages Formation\u2019s clinical development expertise and Pacific Bridge\u2019s capital.<\/li>\n\n\n\n<li><strong>For Pacific Bridge:<\/strong> Minority co\u2011investment provides exposure to <strong>high\u2011value neuroinflammatory pipeline<\/strong> with reduced risk via Formation\u2019s operational leadership.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief includes forward\u2011looking statements regarding LNK01006\u2019s development timeline, milestone achievements, and market projections. Actual results may differ due to preclinical risks, competitive responses, and regulatory challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lynk Pharmaceuticals Co., Ltd. and Formation Bio announced that Bleecker Bio, a newly formed Formation&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50462,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4499,4176,1351],"class_list":["post-50461","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bleecker-bio","tag-formation-bio","tag-lynk-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bleecker Bio (Formation) Licenses Lynk\u2019s CNS\u2011Penetrant TYK2 Inhibitor LNK01006 in $605\u202fM Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lynk Pharmaceuticals Co., Ltd. and Formation Bio announced that Bleecker Bio, a newly formed Formation subsidiary, has secured exclusive global rights (ex\u2011Greater China) to LNK01006, Lynk\u2019s next\u2011generation, CNS\u2011penetrant, allosteric TYK2 inhibitor. Lynk will receive an upfront payment (undisclosed), up to USD\u202f605\u202fmillion in milestones, tiered royalties, and an equity stake in Bleecker Bio. Pacific Bridge NY will co\u2011invest as a minority partner.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50461\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bleecker Bio (Formation) Licenses Lynk\u2019s CNS\u2011Penetrant TYK2 Inhibitor LNK01006 in $605\u202fM Deal\" \/>\n<meta property=\"og:description\" content=\"Lynk Pharmaceuticals Co., Ltd. and Formation Bio announced that Bleecker Bio, a newly formed Formation subsidiary, has secured exclusive global rights (ex\u2011Greater China) to LNK01006, Lynk\u2019s next\u2011generation, CNS\u2011penetrant, allosteric TYK2 inhibitor. Lynk will receive an upfront payment (undisclosed), up to USD\u202f605\u202fmillion in milestones, tiered royalties, and an equity stake in Bleecker Bio. Pacific Bridge NY will co\u2011invest as a minority partner.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50461\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-11T14:43:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-11T14:43:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1106.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50461#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50461\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bleecker Bio (Formation) Licenses Lynk\u2019s CNS\u2011Penetrant TYK2 Inhibitor LNK01006 in $605\u202fM Deal\",\"datePublished\":\"2025-12-11T14:43:25+00:00\",\"dateModified\":\"2025-12-11T14:43:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50461\"},\"wordCount\":411,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50461#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1106.webp\",\"keywords\":[\"Bleecker Bio\",\"Formation Bio\",\"Lynk Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50461#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50461\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50461\",\"name\":\"Bleecker Bio (Formation) Licenses Lynk\u2019s CNS\u2011Penetrant TYK2 Inhibitor LNK01006 in $605\u202fM Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50461#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50461#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1106.webp\",\"datePublished\":\"2025-12-11T14:43:25+00:00\",\"dateModified\":\"2025-12-11T14:43:28+00:00\",\"description\":\"Lynk Pharmaceuticals Co., Ltd. and Formation Bio announced that Bleecker Bio, a newly formed Formation subsidiary, has secured exclusive global rights (ex\u2011Greater China) to LNK01006, Lynk\u2019s next\u2011generation, CNS\u2011penetrant, allosteric TYK2 inhibitor. Lynk will receive an upfront payment (undisclosed), up to USD\u202f605\u202fmillion in milestones, tiered royalties, and an equity stake in Bleecker Bio. Pacific Bridge NY will co\u2011invest as a minority partner.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50461#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50461\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50461#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1106.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1106.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bleecker Bio (Formation) Licenses Lynk\u2019s CNS\u2011Penetrant TYK2 Inhibitor LNK01006 in $605\u202fM Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50461#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bleecker Bio (Formation) Licenses Lynk\u2019s CNS\u2011Penetrant TYK2 Inhibitor LNK01006 in $605\u202fM Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bleecker Bio (Formation) Licenses Lynk\u2019s CNS\u2011Penetrant TYK2 Inhibitor LNK01006 in $605\u202fM Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Lynk Pharmaceuticals Co., Ltd. and Formation Bio announced that Bleecker Bio, a newly formed Formation subsidiary, has secured exclusive global rights (ex\u2011Greater China) to LNK01006, Lynk\u2019s next\u2011generation, CNS\u2011penetrant, allosteric TYK2 inhibitor. Lynk will receive an upfront payment (undisclosed), up to USD\u202f605\u202fmillion in milestones, tiered royalties, and an equity stake in Bleecker Bio. Pacific Bridge NY will co\u2011invest as a minority partner.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50461","og_locale":"en_US","og_type":"article","og_title":"Bleecker Bio (Formation) Licenses Lynk\u2019s CNS\u2011Penetrant TYK2 Inhibitor LNK01006 in $605\u202fM Deal","og_description":"Lynk Pharmaceuticals Co., Ltd. and Formation Bio announced that Bleecker Bio, a newly formed Formation subsidiary, has secured exclusive global rights (ex\u2011Greater China) to LNK01006, Lynk\u2019s next\u2011generation, CNS\u2011penetrant, allosteric TYK2 inhibitor. Lynk will receive an upfront payment (undisclosed), up to USD\u202f605\u202fmillion in milestones, tiered royalties, and an equity stake in Bleecker Bio. Pacific Bridge NY will co\u2011invest as a minority partner.","og_url":"https:\/\/flcube.com\/?p=50461","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-11T14:43:25+00:00","article_modified_time":"2025-12-11T14:43:28+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1106.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50461#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50461"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bleecker Bio (Formation) Licenses Lynk\u2019s CNS\u2011Penetrant TYK2 Inhibitor LNK01006 in $605\u202fM Deal","datePublished":"2025-12-11T14:43:25+00:00","dateModified":"2025-12-11T14:43:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50461"},"wordCount":411,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50461#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1106.webp","keywords":["Bleecker Bio","Formation Bio","Lynk Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50461#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50461","url":"https:\/\/flcube.com\/?p=50461","name":"Bleecker Bio (Formation) Licenses Lynk\u2019s CNS\u2011Penetrant TYK2 Inhibitor LNK01006 in $605\u202fM Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50461#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50461#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1106.webp","datePublished":"2025-12-11T14:43:25+00:00","dateModified":"2025-12-11T14:43:28+00:00","description":"Lynk Pharmaceuticals Co., Ltd. and Formation Bio announced that Bleecker Bio, a newly formed Formation subsidiary, has secured exclusive global rights (ex\u2011Greater China) to LNK01006, Lynk\u2019s next\u2011generation, CNS\u2011penetrant, allosteric TYK2 inhibitor. Lynk will receive an upfront payment (undisclosed), up to USD\u202f605\u202fmillion in milestones, tiered royalties, and an equity stake in Bleecker Bio. Pacific Bridge NY will co\u2011invest as a minority partner.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50461#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50461"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50461#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1106.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1106.webp","width":1080,"height":608,"caption":"Bleecker Bio (Formation) Licenses Lynk\u2019s CNS\u2011Penetrant TYK2 Inhibitor LNK01006 in $605\u202fM Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50461#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bleecker Bio (Formation) Licenses Lynk\u2019s CNS\u2011Penetrant TYK2 Inhibitor LNK01006 in $605\u202fM Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1106.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50461","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50461"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50461\/revisions"}],"predecessor-version":[{"id":50463,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50461\/revisions\/50463"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50462"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50461"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50461"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}